Advances in Clinical and Experimental Medicine

Adv Clin Exp Med
Impact Factor (IF) – 1.227
Index Copernicus (ICV 2018) – 157.72
MNiSW – 40
Average rejection rate – 84.38%
ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download PDF

Advances in Clinical and Experimental Medicine

2014, vol. 23, nr 1, January-February, p. 123–126

Publication type: review article

Language: English

Infections Caused by Chlamydophila pneumoniae

Irena Choroszy-Król1,F, Magdalena Frej-Mądrzak1,D, Martyna Hober1,B, Jolanta Sarowska1,C, Agnieszka Jama-Kmiecik1,A

1 Department of Basic Sciences, Faculty of Health Science, Wroclaw Medical University, Poland

Abstract

High affinity to the epithelial lining of the airways makes Chlamydophila pneumoniae a common etiological agent of respiratory tract infections (RTI). It causes among others: pharyngitis, tracheitis, sinusitis, otitis media, bronchitis and bronchiolitis, and pneumonia. It is estimated that Chlamydophila pneumoniae infection is responsible for about 20% of lower respiratory tract infections. Chlamydophila pneumoniae infection may play an important role in the pathogenesis and course of bronchial asthma. The recent results indicate that Chlamydophila pneumoniae infection may be a factor responsible for 4–16% of COPD (Chronic obstructive pulmonary disease) exacerbations. A relationship of chlamydial infection with atherosclerosis raises huge interest. A connection of Chlamydophila pneumoniae infection with other non-communicable diseases such as lung cancer, arthritis, Alzheimer’s disease, multiple sclerosis, sarcoidosis and erythema nodosum is also recognized, although the role of these bacteria has not been fully understood in any of the listed diseases.

Key words

Chlamydophila pneumoniae, RTI, asthma, COPD.

References (23)

  1. Woźniakowska-Gęsicka T, Wiśniewska-Ligier M, Kiciński P, Gęsicki T: Niedoceniany problem zakażeń chlamydiowych. Przegl Epidemiol 2008, 2, 133–141.
  2. Krenke R: Chlamydophila (Chlamydia) pneumoniae, jako czynnik zakażeń układu oddechowego. Terapia 2006, 14, 45–52.
  3. Jurkiewicz D: Zakażenia górnych dróg oddechowych u dorosłych wywołane przez bakterie atypowe. Pol Merk Lek 2008, 5, 423–425.
  4. Podsiadły E, Tylewska-Wierzbanowska T: Czy Chlamydophila pneumoniae może być czynnikiem etiologicznym chorób nieinfekcyjnych? Post Mikrobiol 2005, 44, 127–136.
  5. Skibińska A, Kruszewski J: Chlamydiozy. Alergia 2002, 21–24.
  6. Pawlikowska M, Deptuła W: Chlamydie i chlamydophile u ludzi i zwierząt. Wydawnictwo Naukowe Uniwersytetu Szczecińskiego, Szczecin 2012.
  7. Jurkiewicz D: Zakażenia górnych dróg oddechowych u dorosłych wywołane przez bakterie atypowe. Pol Merk Lek 2008, 25, 423–425.
  8. Virella G: Mikrobiologia i choroby zakaźne. Wydawnictwo Medyczne Urban& Partner, Wrocław 2000.
  9. Kuo CC, Jackson LA, Campbell LA, Graystonn JT: Chlamydia pneumoniae (TWAR). Clin Microb Rev 1995, 8, 451–461.
  10. Tyl J: Chlamydiowe zakażenia dróg oddechowych u dzieci. Przegl Pediatr 2003, 33, 41–45.
  11. Ewig S, Torres A: Is Chlamydia pneumonie an important pathogen in patients with community acquired pneumonia? Eur Respir J 2003, 21, 741–742.
  12. Nitsch-Osuch A, Choroszy-Król I, Wardyn AK: Zakażenia wywołane przez Chlamydia pneumoniae. Górnicki Wydawnictwo Medyczne, Wrocław 2001.
  13. Hahn DL, McDonald R: Can acute Chlamydia pneumoniae respiratory tract infection initiate chronic astma? Ann. Allergy Astma Immunol 1998, 81, 339–344.
  14. Hansbro PM, Beagley KW, Horvat JC, Gibson PG: Role of atypical bacterial infection of the lung in predisposition/protection of asthma. Pharmacol Ther 2004, 101, 193–210.
  15. Specjalski K: Rola zakażeń Chlamydia pneumoniae i Mycoplasma pneumoniae w przebiegu astmy. Pneumonol Alergol Pol 2010, 78, 284–295.
  16. Jama-Kmiecik A, Choroszy-Król I: Rola Chlamydophila pneumoniae w astmie oskrzelowej i przewlekłej obturacyjnej chorobie płuc – mechanizmy odpowiedzi immunologicznej. Adv Clin Exp Med 2007, 16, 113–121.
  17. Guilbert TW, Denlinger LC: Role of infection in the development and exacerbation of asthma. Expert Rev Respir Med 2010, 4, 71–83.
  18. von Hertzen L, Alakarppa H, Koskinen R: Chlamydia pneumoniae infection in patients with chronic obstructive pulmonary disease. Epidemiol Infect 1997, 118, 155–164.
  19. Pawlikowska M, Deptuła W: Choroby u ludzi spowodowane chlamydiami i chlamydiofilami. Postępy Hig Med Dosw (online), 2007, 61, 708–717.
  20. Fazio G, Giovino M, Gullotti A, Bacarella D, Novo G, Novo S: Atherosclerosis, inflammation and Chlamydia pneumoniae. World J Cardiol 2009, 1, 31–40.
  21. Mussa FF, Chai H, Wang X, Yao Q, Lumsden AB, Chen C: Chlamydia pneumoniae and vascular disease: An update. Journal of Vascular Surgery 2006, 43, 1301–1307.
  22. Watson C, Alp NJ: Role of Chlamydia pneumoniae in atherosclerosis. Clin Sci 2008, 114, 509–531.
  23. Littman AJ, Jackson LA, Vaughan TL: Chlamydia pneumoniae and Lung Cancer: Epidemiologic Evidence. Cancer Epidemiol Biomarkers Prev 2005, 14, 773–778.